Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.
Key Financial Performance
Cash and Investments $270.2 million at the end of Q3 2025, with no debt. This includes $107 million from a secondary public offering in July and $34.3 million from an ATM facility in September. Year-end cash guidance increased to $240 million, up from $100 million to $185 million, due to additional $38.3 million from ATM sales in October. Cash runway extended into Q2 2027.
Noncash Royalty Revenue $11.5 million for Q3 2025, expected to total approximately $40 million for the full year.
R&D Expense $27.3 million for Q3 2025, with full-year guidance between $125 million and $130 million. Includes $5 million to $10 million of noncash depreciation and stock-based compensation expense.
G&A Expense $16.1 million for Q3 2025, with full-year guidance between $70 million and $75 million. Includes $5 million to $10 million of noncash depreciation and stock-based compensation expense.
Noncash Interest Expense $6 million for Q3 2025, expected to total approximately $20 million for the full year.
Noncash Loss from Equity Method Investment $0.5 million for Q3 2025, expected to total approximately $10 million for the full year.
Net Loss $35.5 million for Q3 2025, or $1.87 basic and diluted net loss per share.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
REZPEG Phase III Development: Nektar is advancing its lead program, rezpegaldesleukin (REZPEG), into Phase III development for atopic dermatitis. The program focuses on stimulating Tregs to restore immune system balance.
Phase IIb RESOLVE-AA Study: Nektar plans to present top-line results in December 2025 for REZPEG in alopecia areata, targeting a $1 billion market opportunity.
Type 1 Diabetes Study: TrialNet has initiated a Phase II study of REZPEG in new onset Stage III type 1 diabetes patients.
TNFR2 Agonist Development: Nektar is progressing its TNFR2 agonist, NKTR-0165, with plans to advance it into the clinic next year.
Atopic Dermatitis Market: The U.S. market for moderate to severe atopic dermatitis includes over 15 million people, with fewer than 10% receiving biologic treatments. Nektar sees potential for market growth with novel mechanisms like REZPEG.
Alopecia Areata Market: The U.S. market includes nearly 7 million people, with over 1 million having severe to very severe disease. REZPEG could be the first biologic treatment in this setting.
Financial Position: Nektar ended Q3 2025 with $270.2 million in cash and investments, extending its cash runway into Q2 2027.
R&D and G&A Expenses: R&D expenses for Q3 2025 were $27.3 million, and G&A expenses were $16.1 million. Full-year R&D expenses are expected to range between $125 million and $130 million.
Regulatory Engagement: Nektar plans to hold an end of Phase II meeting with the FDA for REZPEG in atopic dermatitis before the end of 2025.
Pipeline Expansion: Nektar is building a bispecific program based on its TNFR2 agonist mechanism, aiming to advance it into the clinic next year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Development Risks: The company faces uncertainties and risks related to forward-looking statements about the therapeutic potential and future development plans for rezpegaldesleukin (REZPEG). These risks include the potential for clinical trial failures, delays in regulatory approvals, and challenges in meeting FDA requirements for Phase III trials.
Market Adoption Challenges: Despite the potential of REZPEG, there is a risk that the market for atopic dermatitis and alopecia areata treatments may not grow as expected. Current biologic treatments have low adoption rates, and there is uncertainty about whether novel mechanisms like REZPEG will achieve significant market penetration.
Competitive Pressures: The company faces competition from existing treatments like JAK inhibitors and other biologics for conditions such as alopecia areata and atopic dermatitis. These competitors may limit REZPEG's market share, especially if its efficacy or safety profile does not significantly differentiate it from existing options.
Supply Chain and Manufacturing Risks: The development and production of REZPEG and other pipeline products rely on complex manufacturing processes, including PEGylation. Any disruptions in the supply chain or manufacturing could delay clinical trials or commercialization.
Economic and Financial Risks: The company reported a net loss of $35.5 million for the third quarter of 2025 and relies on cash reserves and public offerings to fund operations. There is a risk that financial resources may not be sufficient to sustain operations through the extended cash runway into 2027, especially if clinical trials or regulatory approvals face delays.
Regulatory and Safety Concerns: The only FDA-approved systemic treatments for alopecia areata are JAK inhibitors, which carry black box warnings. While REZPEG aims to provide a safer alternative, any unforeseen safety issues during clinical trials could hinder its approval and market acceptance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future development plans for rezpegaldesleukin (REZPEG): The company plans to advance REZPEG into Phase III development for moderate to severe atopic dermatitis. An end of Phase II meeting with the FDA is expected before the end of the year to review Phase III plans. Additionally, the company will present 52-week maintenance and escape arm data from the RESOLVE-AD study in Q1 2026. The Phase IIb RESOLVE-AA study in alopecia areata will report top-line results in December 2025, with plans to move quickly into Phase III preparations if results are positive.
Market opportunity for REZPEG: The company anticipates significant market opportunities for REZPEG in atopic dermatitis and alopecia areata. In the U.S., over 15 million people have moderate to severe atopic dermatitis, with fewer than 10% receiving biologic treatments. The alopecia areata market represents an additional $1 billion opportunity, with REZPEG potentially being the first biologic treatment in this setting.
Pipeline progression: The company plans to advance its TNFR2 agonist (NKTR-0165) into the clinic next year. This molecule has high specificity for signaling through TNFR2 on Tregs and is being developed for inclusion in bispecific and trispecific constructs.
Type 1 diabetes study: TrialNet has initiated a Phase II study of REZPEG in new onset Stage III type 1 diabetes patients. This study is funded and sponsored by TrialNet.
Financial guidance: The company expects to end 2025 with approximately $240 million in cash and investments, extending its cash runway into Q2 2027. Noncash royalty revenue for 2025 is expected to total approximately $40 million. R&D expenses for the year are projected to range between $125 million and $130 million, while G&A expenses are expected to be between $70 million and $75 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the significance of the upcoming ACAAI data presentation for patients with AD and asthma?
A:The ACAAI presentation will showcase results from a preplanned exploratory analysis using the ACQ-5 asthma control questionnaire. This analysis assesses the comorbidity symptoms of asthma in patients with both atopic dermatitis and asthma. Approximately 25% of atopic dermatitis patients also have asthma, and the study evaluates the effect of REZPEG on asthma control and symptom improvement. This data highlights REZPEG's potential differentiation from other drugs in the class, such as Dupi, and its unique Treg mechanism.
Q:What is the level of interest in REZPEG as a therapy with a remittive effect for atopic dermatitis?
A:There is significant interest in REZPEG due to its Treg mechanism and compelling data, including the escape arm data where placebo non-responders showed exceptional results when switched to REZPEG. This mechanism and data differentiate REZPEG from other drugs and have generated strong inbound interest.
Q:What are the prospects for REZPEG in alopecia areata compared to JAK inhibitors?
A:REZPEG has the potential to be a differentiated mechanism in alopecia areata due to its safety profile, lack of black box warnings, and potential for sustained treatment effects. Unlike JAK inhibitors, which lose efficacy quickly upon treatment interruption, REZPEG may maintain hair regrowth even after stopping treatment. This makes it a promising alternative for chronic conditions like alopecia areata.
Q:When can the Phase III program for alopecia areata start, and will it be conducted independently or in partnership?
A:The Phase III program for alopecia areata could start next year, depending on the December data. The company plans to move forward independently, emphasizing the need for a new modality to treat this serious condition.
Q:Were there any patients with alopecia areata comorbidities in the Phase IIb AD study?
A:Yes, the study looked at multiple comorbidities, including alopecia areata, but the number of patients with alopecia was very small and not sufficient to isolate as a subgroup. The upcoming Phase IIb results in alopecia will provide a more definitive dataset.
Q:Are there any other therapeutics in development for alopecia that could serve as benchmarks for REZPEG?
A:Yes, there are other biologics in development, such as IL-7 receptor agents. However, REZPEG's larger study size and multiple doses provide a more comprehensive assessment of treatment effects. Tregs are a key mechanism in alopecia areata, and REZPEG's ability to elevate Tregs significantly differentiates it from other agents.
Q:What is the primary endpoint for the alopecia areata study, and will there be an off-treatment responder rate reported?
A:The primary endpoint is the mean percent reduction in SALT score from baseline, with key secondary endpoints including SALT 20 and SALT 10. The study includes a 24-week off-drug observation period to assess the maintenance of hair regrowth, but there is no escape arm for placebo non-responders.
Q:What is the status of the auto-injector development for REZPEG?
A:The auto-injector development is ongoing and is planned to be available at the time of REZPEG's launch. Phase III studies will use vials for speed, but the auto-injector will be part of the BLA submission.
Q:What advantages does REZPEG offer over JAK inhibitors for alopecia areata?
A:REZPEG offers a better safety profile, lacks black box warnings, and has the potential for long-term use without rapid loss of efficacy upon treatment interruption. It also provides a psychological advantage by maintaining hair regrowth, unlike JAK inhibitors, which can cause rapid hair loss when stopped.
Q:What are the registrational endpoints for alopecia areata, and how does REZPEG compare to JAK inhibitors like UPA?
A:The registrational endpoints are SALT 20 in the U.S. and SALT 10 in Europe. REZPEG's safety profile and potential for long-term use differentiate it from JAK inhibitors like UPA, which, while effective, have safety concerns and rapid loss of efficacy upon treatment interruption.
Q:What measures were taken to minimize the placebo effect in the RESOLVE-AD study, and will these be implemented in Phase III?
A:The RESOLVE-AD study ensured low placebo effects by involving board-certified dermatologists, verifying eligibility criteria at multiple stages, and maintaining a large placebo group. These measures will be implemented in the Phase III program to ensure consistent results.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about the potential use of REZPEG in asthma, stating that they are not pursuing an asthma indication despite presenting data on its effects on asthma control. Additionally, they did not provide clear details on the timeline or specifics of the auto-injector development beyond stating it would be ready by launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AA study
AD study
Dr Tagliaferri
EADV Congress
III trial
Nektar
Nobel
Phase II
Phase III
Phase IIb
RESOLVE AA
RESOLVE AD
REZPEG dermatitis
Tagliaferri Chief
areata inhibitor
asthma symptom
construct
dermatitis asthma
dermatitis treatment
differentiation
discovery
dose Olumiant
endpoint week
goal antibody
kilogram week
market opportunity
pathway blocker
patient RESOLVE
patient alopecia
period RESOLVE
placebo basis
reduction
setting
significance endpoint
study significance
symptom patient
treatment REZPEG
weekend
NKTR Transcript
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals a negative sentiment due to a 20% decline in revenue and increased net loss, coupled with higher R&D expenses. The lack of strategic initiatives and shareholder return discussion further dampens the outlook. Despite potential in Rezpegaldesleukin, the absence of concrete advancements or partnerships, combined with the risks in forward-looking statements, contributes to a negative sentiment. The cash position decrease also raises concerns about financial health, leading to a likely negative stock price movement.
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. The financial performance shows a decrease in revenue but an improved net loss and positive cash flow, leading to a neutral sentiment. The development plans for Rezpegaldesleukin and future data presentations are positive, but the lack of discussion on shareholder returns and inherent risks in forward-looking statements balance this out. The Q&A section did not provide additional insights to shift the sentiment significantly. Overall, the stock price is likely to remain stable over the next two weeks.
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Positive11-7
Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary indicates a strong financial position and optimistic guidance, which are positive factors. However, there are concerns about high R&D expenses, projected net losses, and ongoing litigation with Lilly. The Q&A reveals management's active engagement in partnerships and confidence in product development, but also highlights uncertainties in litigation and lack of specific benchmarks for remittive effects. These mixed signals suggest a neutral impact on stock price, especially given the absence of a market cap for further context.
NKTR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
